SION
Sionna Therapeutics, Inc. NASDAQ Listed Feb 7, 2025$37.30
+1.55%
vs $36.73
Mkt Cap $1.7B
52w Low $13.81
67.8% of range
52w High $48.45
50d MA $39.91
200d MA $37.20
P/E (TTM)
-19.8x
EV/EBITDA
—
P/B
4.9x
Debt/Equity
0.0x
ROE
-24.5%
P/FCF
-22.4x
RSI (14)
35.00
ATR (14)
$2.73
Beta
3.01
50d MA
$39.91
200d MA
$37.20
Avg Volume
398.6K
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
CIK (SEC)
Phone
617 819 2020
21 Hickory Drive Suite 500 · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | TNS | -0.52 | -0.60 | -15.4% | 40.94 | -0.4% | +5.3% | -0.8% | -6.0% | -2.4% | -4.0% | — |
| May 11, 2026 | BMO | — | — | — | 44.23 | +1.0% | +3.9% | -10.9% | +5.3% | -0.8% | -6.0% | — |
| May 8, 2026 | BMO | — | — | — | 43.31 | +1.4% | +2.1% | +3.9% | -10.9% | +5.3% | -0.8% | — |
| May 7, 2026 | BMO | — | — | — | 43.29 | +0.1% | +0.0% | +2.1% | +3.9% | -10.9% | +5.3% | — |
| Mar 2, 2026 | TNS | -0.54 | -0.46 | +14.7% | 33.92 | +0.0% | +0.5% | +0.0% | +1.4% | -0.0% | +4.0% | — |
| Nov 5, 2025 | TNS | -0.52 | -0.46 | +11.5% | 35.08 | -0.3% | -1.9% | +0.0% | +0.9% | +3.1% | +1.9% | — |
| Aug 11, 2025 | TNS | -0.68 | -0.41 | +39.7% | 20.03 | -0.7% | +4.8% | +0.0% | -0.4% | +0.0% | -0.4% | — |
| May 12, 2025 | TNS | -0.45 | -0.62 | -37.8% | 12.90 | -3.6% | -0.5% | +0.0% | -6.5% | +12.0% | -0.1% | — |
| Mar 20, 2025 | TNS | -0.57 | -3.38 | -493.0% | 13.88 | -1.2% | -1.4% | +0.0% | -11.6% | +6.9% | -6.9% | — |
| Nov 27, 2024 | TNS | — | -0.92 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Wedbush | Initiates | Outperform | $53 | $40.45 | $41.53 | +2.7% | +1.3% | +5.7% | +0.0% | +2.1% | +3.9% |
| Apr 28 | Jones Trading | Maintains | Buy → Buy | — | $39.21 | $39.68 | +1.2% | +1.0% | -5.5% | +3.4% | +1.2% | +3.3% |
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $38.11 | $38.02 | -0.2% | +2.9% | +1.0% | -5.5% | +3.4% | +1.2% |
| Mar 3 | Guggenheim | Maintains | Buy → Buy | — | $33.92 | $33.92 | +0.0% | +0.5% | +1.4% | -0.0% | +4.0% | +4.5% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $36.54 | $32.89 | -10.0% | -7.2% | +0.5% | +1.4% | -0.0% | +4.0% |
| Jan 14 | BTIG | Maintains | Buy → Buy | — | $36.81 | $36.89 | +0.2% | +11.9% | -5.7% | +0.7% | +2.3% | +1.9% |
| Jan 7 | BTIG | Maintains | Buy → Buy | — | $37.22 | $38.14 | +2.5% | +16.1% | -15.3% | +7.2% | -7.4% | +1.3% |
| Dec 1 | RBC Capital | Downgrade | Sector Perform → Underperform | — | $43.57 | $40.76 | -6.4% | -10.6% | +0.1% | +5.5% | -0.7% | -1.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | ORBIMED ADVISORS LLCDir | — | Sell | 184,639 | $46.22 | $8.5M | 2,671,822 | -10.90% | -2.44% |
| May 11, 2026 | Thompson Peter A.Dir | — | Sell | 184,639 | $46.22 | $8.5M | 2,671,822 | -10.90% | -2.44% |
| May 8, 2026 | ORBIMED ADVISORS LLCDir | — | Sell | 59,767 | $44.58 | $2.7M | 2,856,461 | -10.90% | -2.44% |
| May 8, 2026 | Thompson Peter A.Dir | — | Sell | 59,767 | $44.58 | $2.7M | 2,856,461 | -10.90% | -2.44% |
| May 7, 2026 | ORBIMED ADVISORS LLCDir | — | Sell | 48,546 | $44.61 | $2.2M | 2,916,228 | -10.90% | -2.44% |
| May 7, 2026 | Thompson Peter A.Dir | — | Sell | 48,546 | $44.61 | $2.2M | 2,916,228 | -10.90% | -2.44% |
8-K
Sionna Therapeutics, Inc. -- 8-K Filing
Jun 18
8-K · 2.02
!! High
Sionna Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K
Sionna Therapeutics, Inc. -- 8-K Filing
Sionna Therapeutics' successful upsized IPO in February 2025 provided capital momentum for the clinical-stage cystic fibrosis biotech to advance its CFTR-normalizing pipeline while burning cash toward potential clinical milestones.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Viking Global Investors | 3,195,181 | $128M | — | Mar 2026 |
| 2 | Atlas Venture Life Science Advisors, Llc | 2,995,602 | $120M | — | Mar 2026 |
| 3 | Jpmorgan Chase & Co | 1,465,014 | $54M | Added | Mar 2026 |
| 4 | Citadel Advisors Llc | 1,166,931 | $47M | Added | Mar 2026 |
| 5 | Jennison Associates Llc | 1,115,278 | $46M | Added | Dec 2025 |
| 6 | Vanguard Capital Management Llc | 1,029,497 | $41M | New | Mar 2026 |
| 7 | Deerfield Management Company, L.p. | 970,590 | $39M | — | Mar 2026 |
| 8 | Aberdeen Group Plc | 564,175 | $23M | Reduced | Mar 2026 |
| 9 | Soleus Capital Management, L.p. | 293,500 | $12M | Added | Mar 2026 |
| 10 | Ensign Peak Advisors, Inc | 255,636 | $10M | Added | Mar 2026 |
| 11 | Kalehua Capital Management Llc | 197,072 | $8M | — | Mar 2026 |
| 12 | Franklin Resources Inc | 175,483 | $7M | — | Mar 2026 |
| 13 | Ubs Group Ag | 147,641 | $6M | Added | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 142,081 | $6M | New | Mar 2026 |
| 15 | Superstring Capital Management Lp | 141,024 | $6M | Reduced | Mar 2026 |
| 16 | Millennium Management | 140,641 | $6M | Added | Mar 2026 |
| 17 | Point72 Asset Management | 136,549 | $5M | New | Mar 2026 |
| 18 | Alyeska Investment Group, L.p. | 136,222 | $5M | — | Mar 2026 |
| 19 | Gordonmd Global Investments Lp | 136,000 | $5M | New | Mar 2026 |
| 20 | Northern Trust Corp | 116,776 | $5M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.68B
Enterprise Value
$1.25B
P/E (TTM)
-19.84x
Forward P/E
—
PEG Ratio
-0.64x
P/B
4.86x
P/S
—
P/FCF
-22.36x
EV/EBITDA
—
Shares Out
40.0M
Financials (TTM)
Revenue
$0
Net Income
-$75.3M
EBITDA
-$88.3M
Free Cash Flow
-$66.7M
Op Cash Flow
-$66.3M
EPS Basic
$-1.88
EPS Diluted
$-1.88
EPS Forward
$-2.33
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$326.0M
Total Liab.
$19.1M
Total Equity
$306.8M
Cash
$235.9M
LT Debt
$0
Book Value/Sh
$7.68
Debt/Equity
0.03x
Current Ratio
20.61
Quick Ratio
20.61
Returns & Growth
ROE
-24.5%
ROA
-23.1%
ROIC
-28.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
-34.3%
Price Returns
2W
+0.1%
1M
+10.6%
3M
+17.2%
6M
-1.7%
12M
+212.8%
Technicals
52W High
$48.45
52W Low
$13.81
50d MA
$39.91
200d MA
$37.20
RSI (14)
35.00
ATR (14)
$2.73
Beta
3.01
Avg Volume
399K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$46.25
High
$58.00
Low
$24.00
Median
$51.50
Data updated apr 27, 2026 1:21am
· Source: financialmodelingprep.com